PLEASANTON, Calif. — November 13, 2026. A Pleasanton biotechnology company has agreed to pay $528,335.74 to resolve federal allegations that it accepted National Institutes of Health research funding while failing to disclose an eligibility issue involving its principal investigator, according to the U.S. Attorney's Office for the Northern District of California.

What the federal government alleged

Cyion Technologies LLC conducts biological research and drug discovery work. The Justice Department announced the settlement on Friday, November 13, saying the allegations involved two Small Business Technology Transfer (STTR) grants and one Small Business Innovation Research (SBIR) grant from the NIH.

Federal prosecutors said these small-business research award programs prohibit applicant companies from receiving certain grants when the principal investigator holds other full-time employment. The government alleged that Cyion did not disclose such outside employment when it applied for STTR awards in 2017 and an SBIR award in 2023, or during the relevant drawdowns of federal funds through 2019 and 2024, respectively.

Settlement versus a criminal conviction

The $528,335.74 agreement resolves civil allegations under the federal False Claims Act. It is not described as a criminal conviction or a guilty plea. Crucially, the Justice Department explicitly states that the claims resolved are allegations only and that no liability determination has been made.

That distinction matters for local readers and the biotech community. Settlement amounts may reflect an agreement to resolve a dispute and litigation risk without a court deciding whether the underlying conduct occurred exactly as alleged.

Why research-grant compliance matters locally

STTR and SBIR programs support innovation by eligible businesses and small research teams. Their conditions can cover investigator eligibility, outside employment, budget uses and reporting obligations. Failure to understand the conditions may expose grant recipients to audits and potential recovery actions. The Pleasanton matter shows why eligibility records and disclosures are central to federal research funding.

The investigation involved the U.S. Attorney's Office for the Northern District of California and the U.S. Department of Health and Human Services Office of Inspector General. Those with information about possible waste, fraud or abuse in HHS-funded programs can find federal reporting instructions through the HHS-OIG reporting page.

Primary source: U.S. Department of Justice, November 13, 2026. This article reports what the government said and does not assert a finding of wrongdoing.

Help Pleasanton News grow Help strengthen reporting on Pleasanton: community voices, important decisions and local life.
Support Pleasanton News

Choose how to support Pleasanton News:

Credit / Debit Card via Stripe

Choose your contribution amount on the secure California58 Stripe checkout. One-time support for independent local journalism.

Continue with PayPal Continue with Zelle

Zelle payments go to Vitaly Ataev Troshin. Please verify the recipient in your bank before sending. Availability depends on your bank.

Optional reader support. When possible, add “Pleasanton News” to the payment note. Contributions are not advertised as tax-deductible. Support does not influence editorial decisions.

Pleasanton News — Your Community Newspaper

Have a correction, news tip, local announcement, or story to submit? Contact our editorial team. All submissions are reviewed before publication.

Contact the Pleasanton News newsroom →

More from Pleasanton News

Visit Pleasanton News →

СООБЩЕСТВО

Комментарии

Присоединяйтесь к обсуждению California58. Чтобы комментировать, необходимо войти в аккаунт.